6 hours ago
1
Earnings Call Insights: Syndax Pharmaceuticals (SNDX) Q3 2025
Management View
- CEO Michael Metzger stated the company achieved "another outstanding period of commercial and portfolio execution," with $45.9 million in total revenue for the third quarter, marking 21% growth over the prior quarter. Metzger highlighted strong launches
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking Alpha website. The insights are generated by an AI tool and have not been curated or reviewed by editors. Due to inherent limitations in using AI-based tools, the accuracy, completeness, or timeliness of the earnings call insights cannot be guaranteed.
Please see full earnings call transcripts
here.
The earnings call insights are intended for informational purposes only. Seeking Alpha does not take account of your objectives or your financial situation and does not offer any personalized investment advice. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank.
English (US) ·